Nevertheless, progress in personalized treatment is still being achieved; for instance, a recent study conducted by Klimovich et al. states that even partial p53 reactivation can induce cancer regression in mice, when the MUTp53E177R variant is considered. This evidence concerns the gene TP53 and cancer.